#vip sum of last 4 years of cash flow from operations 200 cr, means avg 50 cr. Even if consider latest year normalized value 60-70 cr , one is paying 70-80x cash profit DESPITE so much correction. Hyped story on name of brand, consumer durable , travel theme ? How u justify ?
The same no for 2008-11 was 150 cr. So, from 2008-11 to 2016-19, 8 year increment is from 150 cr to 200 cr (m taking 4 years to normalise working capital effect spreads), 8 years, 33% total absolute growth. That's not even 4% cagr growth in cash profit . Missing something ?
So , ultimately , we r paying min 70x cash profit for a less than 4% cagr cash profit growth story. Why ??
Now some fun facts on shareholding : Jan16 to sept 18, FII went from 0.4 to 12%, price from 96 to 600. After that FII, started selling off. Retail n MF have been buying lapping up 6%+,price is down from 600 to below 400. Business wise not much changed😁
The price in 2012 was 200 n in 2016 went down below 100. No one recognized quality then. May be it was the ITC was 2012-16 😁 before quality emerged once FIIs said - Tathastu . #qualitynarratives
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Yesterday, I shared this data point of % of companies hitting 52 week low close to ILFS Oct 2018 number.
Question is what is the significance of this data?
Let us explore
The reason to share this data is much more interesting. In current market, people would say - do not catch falling knife, let it bottom etc.
What if you invested in all those days when more than 20% companies were making 52 week low?
Can you backtest return of all such scenarios since last 10-20 years?
Got reminded of my Face2Face video done 4 years back where I presented lot of backtested outputs including how your returns would pan out
Here is this data right from 2006. The red bars are % of companies making 52W low
Though some of these metric are gaining popularity now, we had done lot of exploratory analysis and backtesting around these metric 4-5 years back when I was conceptualizing Scientific Investing . You can watch the full video here:
For SMALLCAP 250, based on Q3FY25 results so far:
❓Best performing companies?
❓Attractively valued companies?
❓Both attractively valued and best performing?
🧵to answer all such questions to help to filter interesting ideas for research
For NIFTY NEXT 50, based on Q3FY25 results so far:
❓Best performing companies?
❓Attractively valued companies?
❓Both attractively valued and best performing?
🧵to answer all such questions to help to filter interesting ideas for research
For NIFTY 50, based on Q3FY25 results so far:
❓Best performing companies?
❓Attractively valued companies?
❓Both attractively valued and best performing?
🧵to answer all such questions to help to filter interesting ideas for research
1/15 🚀 Introducing Aarti Pharmalabs Ltd!
They make APIs, Xanthine Derivatives, and offer CDMO/CMO services for drug development and manufacturing.
Let’s break it down step by step! 🧵👇
2/15 🏢 Company Background:
● Originally part of Aarti Industries, Aarti Pharmalabs became a separate entity in 2022.
● Focus: Manufacturing key pharmaceutical ingredients, intermediates, and offering contract manufacturing for drug development.
● Their goal? To supply high-quality ingredients for medicines, energy drinks, and supplements globally.
3/15 🌿 What are APIs (Active Pharmaceutical Ingredients)?
● APIs are the active components in medicines that provide therapeutic effects.
○ Example: The ingredient in cancer, pain relief, and respiratory drugs.
● Intermediates are chemical compounds used to create APIs.
○ Think of intermediates as the building blocks of medicines
➡️ Aarti manufactures both!
RBI released Financial Stability Report - Dec 2024 (half yearly publication covering financial sector)
🧵 sharing key insights and visuals from the report covering macro, banking, investment and other regulatory aspects after going through the report
To start with market, how much the EPS needs to grow to justify the existing valuation against historic multiple.
Against this, Q2 growth was below 10% YoY
Do track our newsletters where we cover such things in detail on quarterly basis:
Subscribe to Newsletters: scientificinvesting.in